Mednarodni projekti
BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL
Raziskovalci (2)
| št. |
Evidenčna št. |
Ime in priimek |
Razisk. področje |
Vloga |
Obdobje |
Štev. publikacijŠtev. publikacij |
| 1. |
21455 |
dr. Rok Dreu |
Farmacija |
Raziskovalec |
2022 - 2024 |
0 |
| 2. |
12443 |
dr. Irena Mlinarič Raščan |
Farmacija |
Nekdanji/sekundarni vodja |
2022 - 2024 |
0 |
Organizacije (1)
| št. |
Evidenčna št. |
Razisk. organizacija |
Kraj |
Matična številka |
Štev. publikacijŠtev. publikacij |
| 1. |
0510 |
Univerza v Ljubljani |
Ljubljana |
5085063 |
0 |
Povzetek
REMEDI4ALL aims to establish Europe's leadership globally in the repurposing of medicines by creating a vibrant community of practice covering all relevant sectors and disciplines. REMEDI4ALL will establish and operate a permanent European research and innovation platform comprising the complete value chain for cutting edge, patient-focused repurposing, collaborating with users to execute high potential projects at any phase of development, upskilling all stakeholder groups through a comprehensive education and training portfolio, and advancing cross-sectoral policy dialogue with all relevant stakeholders and thought leaders. The tools and processes developed assembled in REMEDI4ALL will be validated in a portfolio of 4 ambitious preclinical and clinical phase demonstrators, representing high patient need in a variety of disease areas, including oncology, rare and infectious diseases.The REMEDI4ALL platform will operate a complete, harmonised and accessible value chain integrating the scientific, methodological, financial, legal, regulatory, and intellectual property aspects of the repurposing approach in a goal-oriented and patient-centric approach. Working closely together with research funders and the patient community, REMEDI4ALL will engage and support a substantial user base and concomitant investments through a permanently sustainable entity, working closely with the permanent European Infrastructures and partners. The community of practice comprises leading academic and clinical facilities and infrastructures, medicines regulators, health technology assessors, public agencies and funders, small and large industry, state-of-the-art artificial intelligence and in silico tools, and a global network of collaborators for optimal knowledge exchange. REMEDI4ALL will substantially increase Europe's capacity to develop high quality repurposed medicines and implement them into market, through its complete value chain and consensus-based policy development mission.
